Position in NGNE
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$247,447
+$228,699 QoQ
Shares Held
7,868
+746.0% QoQ
Ownership
0.039%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#65
of 111 holders
Holding Since
Mar 2024
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NGNE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CITIGROUP INC holds $2,077,377,990 across 384 Biotechnology names. NGNE ranks #202 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
706,968 | $351,172,214 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
346,637 | $216,142,034 | |
| 3 | MRNA |
Moderna, Inc.
|
2,165,414 | $151,643,941 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
2,225,190 | $78,749,472 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
227,786 | $68,570,419 | |
| 6 | INCY |
Incyte Corp
|
586,431 | $66,477,817 | |
| 7 | BBIO |
BridgeBio Pharma, Inc.
|
864,101 | $64,358,241 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
247,052 | $46,267,897 |
All Filings in NGNE
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $247,447 | 7,868 | Shares | Defined | 2026-08-03 | |
| 2026-03-31 | $18,748 | 930 | Shares | Defined | 2026-05-11 | |
| 2025-12-31 | $15,531 | 754 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $6,741 | 389 | Shares | Defined | 2025-11-10 | |
| 2025-06-30 | $53,445 | 3,575 | Shares | Defined | 2025-08-11 | |
| 2025-03-31 | $100,424 | 8,576 | Shares | Defined | 2025-05-12 | |
| 2024-12-31 | $185,165 | 8,100 | Shares | Defined | 2025-02-12 | |
| 2024-09-30 | $313,105 | 7,462 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $82,787 | 2,275 | Shares | Defined | 2024-08-12 | |
| 2024-03-31 | $891,818 | 17,521 | Shares | Defined | 2024-05-10 | |
| No filing history on record for this holder in this stock. | ||||||